ArriVent 10-Q: $40.3M Q3 Loss, $393.2M Cash to Mid-2028, Firmonertinib Patent Claims Confirmed
AVBP sits 25% above its 52-week low of $11.36.
Summary
ArriVent's Q3 10-Q confirms a $40.3M net loss and $393.2M in cash funding operations to mid-2028, and discloses that the USPTO intends to confirm all claims of the reexamined RE '687 firmonertinib patent.
Key Events · Earnings and Guidance · AVBP
-
Q3 Loss Widens on Higher R&D
Net loss was $40.3M ($0.81 per share) versus $34.98M a year ago; nine-month net loss was $133.5M versus $130.8M. Q3 R&D rose to $38.9M from $32.2M and G&A to $9.5M from $6.2M.
-
Cash Runway to Mid-2028
Cash, cash equivalents and short-term investments totaled $393.2M at September 30, 2026, which management says funds operations to mid-2028; accumulated deficit is $538.2M.
-
Firmonertinib Patent Claims Confirmed
On October 19, 2026 the USPTO closed prosecution of the ex parte reexamination of U.S. Reissue Patent 48,687 and indicated it intends to issue a certificate confirming all claims, easing a patent overhang disclosed in the prior 10-Q.
-
ATM Sold $199.6M, $167.9M Left
ArriVent sold 7,318,460 shares under its at-the-market program in the first nine months of 2026 for $199.6M net proceeds, leaving about $167.9M available under the Sale Agreement.
Analysis · AVBP · Life Sciences
Two items in this 10-Q carry more weight than the headline numbers it shares with this morning's 8-K. The first is the patent overhang on the lead asset: the USPTO closed prosecution of the ex parte reexamination of the RE '687 firmonertinib patent on October 19, 2026 and intends to issue a certificate confirming all claims. The second is financing: the company sold 7,318,460 ATM shares for $199.6M net in the first nine months, leaving roughly $167.9M of capacity. The rest is familiar — a $40.3M third-quarter net loss and $393.2M of cash and investments that management says funds operations to mid-2028. Against a lead program that missed its Phase 3 FURVENT endpoint in October, the runway and intact patent matter more than the quarter's loss.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AVBP was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $11.36 to $35.83. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.